The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.
Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial ...
Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire.
Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, ...
(RTTNews) - Biopharmaceutical major Novo Nordisk A/S (NVO) announced on Monday that it has agreed to acquire ocedurenone for uncontrolled hypertension from ...
The Danish pharma announced Monday that it is buying a Phase III hypertension candidate from Singapore-based KBP Biosciences. It is Novo Nordisk's third ...
Novo Nordisk has agreed to pay up to $1.3 billion for KBP Biosciences' phase 3 challenger to Bayer's chronic kidney disease drug Kerendia.
Novo Nordisk has agreed to acquire ocedurenone, a drug for uncontrolled hypertension, from KBP Biosciences in a deal worth up to $1.3bn.